Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replagal Extension in Fabry Disease
NCT01124643Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2010
- Primary completion
- Jul 2013
- Modality
- Replacement Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of agalsidase alfa in Fabry disease (FD), sponsored by Takeda. Started Apr 2010; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT01124643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01124643.